Achieve Life Sciences (QUIT) Stock Price, News & Analysis

Company Overview

Achieve Life Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for nicotine dependence. Its lead product candidate, cytisinicline, is being studied as a potential aid for people seeking to stop smoking or using other nicotine products.

Cytisinicline is a plant-derived compound that acts on nicotine receptors in the brain. The company is conducting clinical development with the goal of obtaining regulatory approval; the candidate is not an approved treatment.

Achieve’s work centers on developing cytisinicline for markets including the United States. The compound has a history of use for smoking cessation in some countries outside the United States, while Achieve is pursuing its own clinical and regulatory pathway.

Key Stats

• Today's Range: $6.20 to $6.50
• 50-Day Range: N/A
• 52-Week Range: $2.62 to $8.64
• Volume: 802,802 shs
• Average Volume: 1.28 million shs
• Market Capitalization: $692.09 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Reduce

Achieve Life Sciences Stock Analysis - MarketRank™

Achieve Life Sciences scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.2 / 5
• Analyst Rating: Reduce

Consensus Rating

Achieve Life Sciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

Achieve Life Sciences has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.7 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Achieve Life Sciences are expected to grow in the coming year, from ($0.92) to ($0.57) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Achieve Life Sciences is -4.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Achieve Life Sciences has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for QUIT.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Achieve Life Sciences does not currently pay a dividend.

Dividend Growth

Achieve Life Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 1.7 / 5
• News Sentiment: -0.33

News Sentiment

Achieve Life Sciences has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Achieve Life Sciences this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for QUIT on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.80% of the stock of Achieve Life Sciences is held by insiders.

Percentage Held by Institutions

33.52% of the stock of Achieve Life Sciences is held by institutions.

Company Calendar

• Today: 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:QUIT
• CIK: N/A
• Web: www.achievelifesciences.com
• Phone: (425) 686-1500
• Fax: 425-686-1600
• Employees: 28
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.65 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -127.13%
• Return on Assets: -53.42%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 10.49
• Quick Ratio: 0.95

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.64 per share
• Price / Book: 3.84

Miscellaneous

• Outstanding Shares: 110,030,000
• Free Float: 101,050,000
• Market Cap: $692.09 million
• Optionable: Optionable
• Beta: 2.42